DexCom v. Abbott Laboratories: Federal Circuit CGM Patent Appeal Voluntarily Dismissed
DexCom appealed an invalidity or cancellation action brought by Abbott Laboratories targeting US11000213B2, which covers systems and methods for processing analyte sensor data for CGM calibration. The Federal Circuit proceeding was voluntarily dismissed by mutual agreement under FRAP 42(b) after 511 days, with each side bearing its own costs — leaving the underlying patent dispute unresolved on the merits.
DexCom and Abbott settle their Federal Circuit standoff quietly
DexCom, Inc. filed Federal Circuit appeal No. 24-1506 on 22 February 2024, challenging a lower-tribunal decision in an invalidity or cancellation action brought by Abbott Laboratories targeting US11000213B2. That patent, filed under application No. US17/076716, protects systems and methods for processing analyte sensor data for sensor calibration — a core element of continuous glucose monitoring (CGM) technology that underpins DexCom’s product line and competitive differentiation against Abbott’s competing Libre platform.
The proceeding closed on 17 July 2025 when the parties jointly agreed to dismiss the appeal under Federal Rule of Appellate Procedure 42(b). The Federal Circuit entered the dismissal by order, with each side bearing its own costs. Crucially, no merits ruling was issued: the court did not affirm, reverse, or vacate the underlying decision, meaning the patent’s validity status as determined in the lower proceeding technically stands, but was not endorsed or reviewed by the Federal Circuit on substance.
A voluntary dismissal at the appellate stage — particularly in a high-stakes CGM patent dispute between two direct market competitors — typically signals a negotiated resolution, whether a licensing arrangement, cross-licence, or broader commercial settlement. The public record does not disclose the terms of any agreement. The 511-day duration suggests substantive engagement before resolution. What remains unknown is whether Abbott retains any licence to the ‘213 patent going forward, and whether further PTAB or district court proceedings between these parties remain live.
Filing to Voluntary dismissal in 511 days
511 days — longer than the median Federal Circuit appeal resolution (~12–14 months)
Voluntarily dismissed at the Federal Circuit: what the order means for both parties
FRAP 42(b) dismissal: no merits adjudication
Federal Rule of Appellate Procedure 42(b) permits parties to dismiss an appeal by stipulation at any time. The Federal Circuit’s order reflects mutual agreement — not a court finding on patentability, obviousness, or any substantive question. The underlying tribunal’s decision technically remains in place, but the Federal Circuit issued no opinion reviewing or endorsing it. This is a procedural endpoint, not a legal verdict on the ‘213 patent’s validity.
Procedural dismissal — no merits rulingWith or without prejudice? The public record is silent
The order records a voluntary dismissal but does not specify whether it is with or without prejudice to any further challenge to US11000213B2. FRAP 42(b) dismissals are generally silent on preclusive effect unless the parties’ stipulation specifies otherwise — and that stipulation is not publicly filed here. IP professionals should not assume the dismissal bars Abbott from future invalidity challenges; equally, they should not assume DexCom has secured permanent protection.
Prejudice terms not publicPatent survives the appeal — but validity was never confirmed
For DexCom, the dismissal means the Federal Circuit did not overturn whatever decision issued below. US11000213B2 remains on the register and is presumably enforceable. However, the absence of a Federal Circuit merits ruling means DexCom cannot point to appellate validation of the patent’s validity. Competitors and potential infringers may still view the ‘213 patent as challengeable, particularly if the lower-tribunal proceeding had identified vulnerabilities.
Patent intact — no appellate endorsementAbbott exits the appeal without a Federal Circuit win on invalidity
Abbott’s agreement to dismiss suggests it either achieved its commercial objectives through negotiation or assessed the appellate risk as unfavourable. Without a Federal Circuit ruling in its favour, Abbott cannot cite this proceeding as precedent supporting invalidity of the ‘213 patent. Any future product launches or CGM system designs by Abbott that touch the ‘213 patent’s claims will still need to account for that patent’s enforceability — unless a licence or covenant has been privately secured.
No Federal Circuit invalidity ruling securedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | DexCom, Inc. | Company | Continuous glucose monitoring technology company — holder of US11000213B2Search in Eureka ↗ |
| Defendant | Abbott Laboratories, Inc. | Company | Global diagnostics and medical device company; maker of the FreeStyle Libre CGM platformSearch in Eureka ↗ |
| Plaintiff counsel | Elisabeth H. Hunt | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gregory S. Nieberg | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nathan R. Speed | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard F. Giunta | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Wolf Greenfield & Sacks PC | Law Firm | Representing DexCom, Inc.Search in Eureka ↗ |
| Defendant counsel | Eliot Damon Williams | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant law firm | Baker Botts LLP | Law Firm | Representing Abbott Laboratories, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s dismissal order is terse by design: it records mutual agreement under FRAP 42(b) and allocates costs equally, but says nothing about the merits of the underlying patentability dispute. This phrasing is consistent with a negotiated resolution rather than litigation fatigue or procedural default. The equal cost allocation — rather than any fee-shifting — suggests neither party was positioned to argue bad faith or exceptional case status. The absence of any opinion means this order creates no precedent on the validity or scope of US11000213B2.
US11000213B2 — CGM sensor data processing and calibration system
US11000213B2, filed under application number US17/076716, protects systems and methods for processing analyte sensor data for sensor calibration in the context of continuous glucose monitoring. Sensor calibration is a critical technical function in CGM devices: raw electrochemical signals from subcutaneous glucose sensors must be converted into accurate blood glucose readings through data processing algorithms that compensate for sensor drift, physiological variability, and calibration artefacts. Patents in this domain govern a foundational layer of CGM product performance.
For DexCom, the ‘213 patent represents IP that sits at the intersection of hardware and software in its CGM platform — an area where Abbott’s FreeStyle Libre system directly competes. Calibration methodology patents are strategically significant because they are difficult to design around without affecting sensor accuracy, a performance metric that is both clinically and commercially critical. Abbott’s invalidity challenge, and DexCom’s appeal, reflects how central this technology class is to competitive differentiation. Any medtech company developing wearable analyte sensors, closed-loop insulin delivery systems, or next-generation biosensors should treat this patent as a live enforcement risk.
Should your CGM or biosensor product run an FTO against US11000213B2?
Any organisation developing continuous glucose monitors, wearable analyte sensors, or sensor data processing software that includes calibration algorithms should conduct a freedom-to-operate analysis against US11000213B2. The patent’s focus on data processing methods — rather than purely physical sensor hardware — means its claims may read on software implementations, embedded firmware, and cloud-based calibration services as well as physical devices. R&D teams building next-generation CGM or closed-loop systems should not assume hardware design-arounds are sufficient.
PatSnap Eureka’s FTO Search Agent allows you to map your sensor calibration architecture against the claim language of US11000213B2, identify potentially overlapping claim elements, and surface relevant prior art that could support a design-around or invalidity argument. With the Federal Circuit appeal now dismissed without a merits ruling, the patent carries full presumption of validity — making proactive FTO analysis more important, not less, for any competitor operating in the CGM or continuous analyte monitoring space.
Run a freedom-to-operate analysis on US11000213B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit CGM and biosensor patent invalidity appeals
Cases involving continuous glucose monitoring sensor patents at the Federal Circuit, including PTAB-origin invalidity appeals in the medtech and wearable diagnostics sector.
What this case signals for the CGM and wearable diagnostics IP landscape
A quietly resolved Federal Circuit appeal between the two dominant CGM players carries strategic weight well beyond the docket.
Voluntary FRAP 42(b) dismissals often mask deeper commercial deals
When direct competitors dismiss a Federal Circuit appeal by stipulation with each side bearing costs, it consistently suggests a parallel commercial resolution — licensing, cross-licence, or a non-assertion covenant. Companies monitoring the DexCom–Abbott IP relationship should watch for SEC disclosures, licensing revenue changes, or product launch patterns that may reveal the deal’s contours.
US11000213B2 remains an active enforcement risk for CGM sensor makers
The ‘213 patent’s claims on analyte sensor data processing and calibration methods sit at the technical core of modern CGM systems. Without a Federal Circuit invalidity ruling, the patent carries full presumption of validity. Any competitor developing sensor calibration algorithms or multi-sensor fusion architectures should conduct FTO analysis against this patent before commercialisation.
DexCom v Abbott — key questions answered
The Federal Circuit appeal in case 24-1506 was voluntarily dismissed by stipulation of both parties under FRAP 42(b) on 17 July 2025. No merits ruling was issued on the validity of US11000213B2. Each party bears its own appellate costs. The case arose from an invalidity or cancellation action by Abbott targeting DexCom’s CGM sensor calibration patent.
US11000213B2 covers systems and methods for processing analyte sensor data for calibration in continuous glucose monitoring devices. Abbott, as maker of the competing FreeStyle Libre CGM platform, challenged its validity in what appears to be a cancellation or inter partes review-type proceeding. Sensor calibration IP is central to CGM performance differentiation, making it a high-value target for validity challenges by direct competitors.
No. A FRAP 42(b) dismissal is procedural — it reflects the parties’ agreement to end the appeal, not a court finding on patentability. The patent retains its statutory presumption of validity, but the Federal Circuit issued no opinion reviewing or endorsing that validity. The dismissal should not be cited as appellate confirmation of the patent’s validity claims.
Equal cost allocation under FRAP 39 is consistent with a negotiated resolution where neither party sought to characterise the other’s conduct as frivolous or made in bad faith. It rules out a fee-shifting outcome under 35 U.S.C. § 285 at the appellate level. It also provides no financial signal about which party was in the stronger litigation position at the time of settlement.
Competitors and entrants in the continuous glucose monitoring space should (1) treat US11000213B2 as a live, enforceable patent given the absence of a Federal Circuit invalidity ruling; (2) conduct FTO analysis against the patent’s claims, particularly if developing sensor calibration algorithms or data processing methods; and (3) monitor DexCom and Abbott’s subsequent licensing disclosures or product launches for signals of any underlying commercial agreement reached in connection with this dismissal.
PatSnap Eureka searches patents and litigation data to answer instantly.